Stephen K. Doberstein

2017

In 2017, Stephen K. Doberstein earned a total compensation of $7.7M as Senior Vice President and Chief Research and Development Officer at Nektar Therapeutics, a 347% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$525,000
Option Awards$3,672,084
Salary$529,084
Stock Awards$2,958,794
Other$13,988
Total$7,698,950

Doberstein received $3.7M in option awards, accounting for 47.70% of the total pay in 2017.

Doberstein also received $525K in non-equity incentive plan, $529.1K in salary, $3M in stock awards and $14K in other compensation.

Rankings

In 2017, Stephen K. Doberstein's compensation ranked 966th out of 14,102 executives tracked by ExecPay. In other words, Doberstein earned more than 93.1% of executives.

ClassificationRankingPercentile
All
966
out of 14,102
93rd
Division
Manufacturing
331
out of 5,593
94th
Major group
Chemicals And Allied Products
85
out of 1,980
96th
Industry group
Drugs
56
out of 1,641
97th
Industry
Pharmaceutical Preparations
48
out of 1,265
96th
Source: SEC filing on April 30, 2018.

Doberstein's colleagues

We found four more compensation records of executives who worked with Stephen K. Doberstein at Nektar Therapeutics in 2017.

2017

Howard Robin

Nektar Therapeutics

Chief Executive Officer

2017

John Nicholson

Nektar Therapeutics

Chief Operating Officer

2017

Gil Labrucherie

Nektar Therapeutics

Chief Financial Officer

2017

Maninder Hora

Nektar Therapeutics

Senior Vice President Pharmaceutical Development and Chief Technical Operations Officer

News

You may also like